Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 20 de 80 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2018;18:febrero. [Ref.ID 102909]
3. Cita con resumen
Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]
4.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S, Grossman E. Adverse effects and tolerability of ß blockers. BMJ 2016;353:i3142. [Ref.ID 100378]
6.Tiene citas relacionadas Cita con resumen
Jaspers L, Feys F, Franco OH, Leusink P, Laan ETM. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women. A systematic review and meta-analysis. JAMA Intern Med 2016;176:453-62. [Ref.ID 100072]
7.Tiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin. Even the score does not add up . JAMA Intern Med 2016;176:439-42. [Ref.ID 100071]
8. Cita con resumen
Young K. FDA advisers back approval of first drug for female sexual dysfunction. Journal Watch 2015:1. [Ref.ID 99241]
9. Cita con resumen
Thorlund K, Druyts E, Wu P, Balijepalli C, Keohane D, Mills E. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc 2015;63:1002-9. [Ref.ID 99078]
10. Cita con resumen
Warlé-van Herwaarden MF, Valkhoff VE, Herings RMC, Engelkes M, van Blijderveen JC, Rodenburg EM, de Bie S, Alsma J, van de Steeg-Gompel C, Kramers C, Meyboom RHB, Sturkenboom MCJM, De Smet PAGM. Quick assessment of drug-related admissions over time (QUADRAT study). Pharmacoepidemiol Drug Saf 2015;24:495-503. [Ref.ID 98885]
11.Tiene citas relacionadas Cita con resumen
Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator P-G, Burcklen M, Stefani M, D'Ambrosio D. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014;384:2036-45. [Ref.ID 98424]
12.Tiene citas relacionadas
Ryan C, Menter A. Ponesimod - a future oral therapy for psoriasis?. Lancet 2014;384:2006-8. [Ref.ID 98423]
13. Cita con resumen
Moynihan R. Evening the score on sex drugs: feminist movement or marketing masquerade?. BMJ 2014;349:g6246. [Ref.ID 98287]
14. Cita con resumen
Anónimo. FDA approves olodaterol for COPD. DIA Daily 2014:1 de agosto. [Ref.ID 97759]
16. Cita con resumen
Stokley S, Jeyarajah J, Yankey D, Yankey D, Gee J, Roark J, Curtis CR, Markowitz L. Human Papillomavirus Vaccination Coverage among Adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014 — United States. Morbidity and Mortality Weekly Report 2014;63:620-4. [Ref.ID 97744]
17. Cita con resumen
Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Research 2014;216:67-73. [Ref.ID 97503]
18. Cita con resumen
Anónimo. Perampanel (Fycompa) for epilepsy. Med Lett Drugs Ther 2014;56:9-10. [Ref.ID 97220]
20.Tiene citas relacionadas
Swigris JJ, Brown KK, Belkin A. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med 2013;158:498. [Ref.ID 95108]
Seleccionar todas
 
 1 a 20 de 80 siguiente >>